Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Appoints New Members to its Board of Directors and Scientific Advisory Board
Immunex’s Executive Vice President Douglas E. Williams, Ph.D. Added to Board of Directors Noted Cancer Expert Dan L. Longo, M.D. Added to Scientific Advisory Board Bothell, WA – May 17, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the appointment of new members to both its Board of
View HTML
Toggle Summary Seattle Genetics Scheduled at CIBC World Markets Bio-Technology Conference
Bothell, WA — May 1, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Scientific Officer, will speak at the CIBC World Markets First Annual Bio-Technology Conference on May 2, 2001 at 10:25 a.m. Eastern Time.
View HTML
Toggle Summary Seattle Genetics Reports First Quarter Results
Bothell, WA — April 24, 2001— Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for its first quarter ended March 31, 2001. Net loss for the quarter was $4.2 million, or $0.46 per share, compared to a net loss of $0.9 million, or $.30 per share for the same period in 2000.
View HTML
Toggle Summary Seattle Genetics Announces Initial Public Offering
Bothell, WA – March 7, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the pricing of its initial public offering of 7,000,000 shares of common stock at $7.00 per share. The offering includes a $2 million investment, or 285,714 shares, purchased directly by Genentech, Inc.
View HTML
Toggle Summary Seattle Genetics and Medarex Establish Alliance to Develop Human Antibody Therapeutics
Medarex to invest $2 million in Seattle Genetics Bothell, WA and Princeton, NJ: February 7, 2001— Seattle Genetics, Inc. and Medarex, Inc. (Nasdaq: MEDX) today announced the formation of a strategic alliance through which the two companies expect to utilize Medarex's UltiMAb™ Human Antibody
View HTML
Toggle Summary Seattle Genetics Initiates Phase II Clinical Trial in Prostate Cancer
Bothell, WA – November 30, 2000 – Seattle Genetics, Inc. announced the initiation of a phase II clinical trial with one of its lead drug candidates, SGN-15. The trial will evaluate the monoclonal antibody-drug conjugate SGN-15 in combination with the chemotherapeutic drug Taxotere® for patients
View HTML
Toggle Summary Seattle Genetics Files For Initial Public Offering of Common Stock
Bothell, WA - November 20, 2000 - Seattle Genetics, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for an initial public offering of its common stock. All of the shares to be registered will be offered by Seattle Genetics. J.P.
View HTML
Toggle Summary Seattle Genetics Signs Development and Manufacturing Agreement with ICOS
Bothell, WA - November 9, 2000 – Seattle Genetics, Inc. announced today that it has signed a development and manufacturing agreement with ICOS Corporation (Nasdaq:ICOS). Under the terms of the agreement, ICOS will conduct development, scale-up and manufacturing in its cell culture manufacturing
View HTML
Toggle Summary Seattle Genetics Initiates Phase II Clinical Trials With SGN-15
Two Trials Commencing for Patients With Breast or Colorectal Cancers Bothell, WA – October 31, 2000 – Seattle Genetics, Inc. announced the initiation of phase II clinical testing with one of its lead monoclonal antibody drug conjugates, SGN-15. “We are very excited to progress into phase II with
View HTML
Toggle Summary Seattle Genetics Initiates Phase I Clinical Trial of SGN-10 in Combination with Taxotere for Patients with Carcinoma
Bothell, WA – September 19, 2000 – Seattle Genetics, Inc. announced the initiation of a second phase I clinical trial with its single-chain immunotoxin, SGN-10. This study will evaluate SGN-10 in combination with Taxotere® for patients with advanced carcinoma.
View HTML